Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations molecular markers of PTC

Histopathology

Volumn 45, Issue 1, 2004, Pages 39-46

  Prasad, M L ^a   Huang, Y ^a   Pellegata, N S ^a   De La Chapelle, A ^a,b,c   Kloos, R T ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

CITED1; Galectin 3; Gene expression; Hashimoto's thyroiditis; Papillary thyroid carcinoma

Indexed keywords

CELL PROTEIN; CYTOKERATIN 19; FIBRONECTIN; GALECTIN 3; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID PAPILLARY CARCINOMA; TISSUE DISTRIBUTION; UPREGULATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, PAPILLARY; CELL NUCLEUS; FEMALE; FIBRONECTINS; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS; THYROIDITIS, AUTOIMMUNE; TUMOR MARKERS, BIOLOGICAL;

EID: 3242765926     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01876.x     Document Type: Article

References (37)

1. Stephenson TJ. Papillary carcinoma of the thyroid: a tumour still with no benign neoplastic counterpart. Histopathology 2001; 39; 536-538.
2. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr. A population-based case-control study of thyroid cancer. J. Natl Cancer Inst. 1987; 79; 1-12.
3. Dailey ME, Lindsay S, Skahen R. Relation of the thyroid neoplasms to Hashimoto's disease of the thyroid gland. Arch. Surg. 1955 70; 291-297.
4. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 2002; 41; 357-362.
5. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 1999; 126; 1070-1076.
6. Ott RA, McCall AR, McHenry C et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am. Surg. 1987; 53; 442-445.
7. Strauss M, Laurian N, Antebi E. Coexistent carcinoma of the thyroid gland and Hashimoto's thyroiditis. Surg. Gynecol. Obstet. 1983; 157; 228-232.
8. Chesky VE, Helwig CA, Welch JW. Cancer of the thyroid associated with Hashimoto's disease. An analysis of 48 cases. Am. Surg. 1961; 28; 678-685.
9. Meier DW, Woolner LB, Beahrs OH, McConahey WH. Parenchymal findings in thyroid carcinoma. Pathologic study of 256 cases. J. Clin. Endocrinol. Metab. 1959; 19; 167.
10. Shands WC. Carcinoma of the thyroid in association with struma lymphomatosa (Hashimoto's disease). Ann. Surg. 1960; 151; 657-682.
11. Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int. J. Surg. Pathol. 2002; 10; 141-146.
12. Sheils O, Smyth P, Finn S, Sweeney EC, O'Leary JJ. RET/PTC rearrangements in Hashimoto's thyroiditis. Int. J. Surg. Pathol. 2002; 10; 167-169.
13. Smyth P, Sheils O, Finn S, Martin C, O'Leary J, Sweeney EC. Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms. Int. J. Surg. Pathol. 2001; 9; 265-272.
14. Holm LE, Blomgren H, Lowenhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N. Engl. J. Med. 1985; 312; 601-606.
15. Crile G. Struma lymphomatosa and carcinoma of the thyroid. Surg. Gynecol. Obstet. 1978; 147; 350-352.
16. Crile G, Hazard JB. Incidence of cancer in struma lymphomatosa. Surg. Gynecol. Obstet. 1962; 115; 101-103.
17. Berho M, Suster S. Clear nuclear changes in Hashimoto's thyroiditis. A clinicopathologic study of 12 cases. Ann. Clin. Lab. Sci. 1995; 25; 513-521.
18. Di Pasquale M, Rothstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum. Pathol. 2001; 32; 24-30.
19. Huang Y, Prasad M, Lemon WJ et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 2001; 98; 15044-15049.
20. Dumic J, Laue G, Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol. Biochem. 2000; 10; 149-158.
21. Fogel S, Guittaut M, Legrand A, Monsigny M, Hebert E. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology 1999; 9; 383-387.
22. Chiariotti L, Berlingieri MT, De Rosa P et al. Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 1992; 7; 2507-2511.
23. Fernandez PL, Merino MJ, Gomez M et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J. Pathol. 1997; 181; 80-86.
24. Yoshii T, Inohara H, Takenaka Y et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int. J. Oncol. 2001; 18; 787-792.
25. Fenner MH, Parrish JE, Boyd Y et al. MSG1 (melanocyte-specific gene 1): mapping to chromosome Xq13.1, genomic organization, and promoter analysis. Genomics 1998; 51; 401-407.
26. Shioda T, Fenner MH, Isselbacher KJ. MSG1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc. Natl Acad. Sci. USA 1996; 93; 12298-12303.
27. Ryu S, Jimi S, Takebayashi S. Thyroid carcinoma distinctively expresses intracellular fibronectin in vivo. Cancer Lett. 1997; 121; 189-193.
28. Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N. Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res. 1997; 57; 3792-3797.
29. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 2001; 14; 338-342.
30. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002; 41; 236-243.
31. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg. 2001; 25; 632-637.
32. Schaffler A, Palitzsch KD, Seiffarth C et al. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur. J. Clin. Invest. 1998; 28; 838-844.
33. Ott RA, Calandra DB, McCall A, Shah KH, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery 1985; 98; 1202-1206.
34. Coli A, Bigotti G, Zucchetti F, Negro F, Massi G. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002; 40; 80-87.
35. Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors; evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003; 88; 2318-2326.
36. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63; 1454-1457.
37. Sheils OM, O'Leary JJ, Uhlmann V, Lüttich K, Sweeney EC. ret/PTC-1 activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 2000; 8; 185-189.